Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy

Journal of Clinical Epidemiology

Volumn 62, Issue 6, 2009, Pages 632-641

  Young, Jim ^a   Glass, Tracy R ^a   Bernasconi, Enos ^b   Rickenbach, Martin ^c   Furrer, Hansjakob ^d   Hirschel, Bernard ^e   Tarr, Philip E ^c   Vernazza, Pietro ^f   Battegay, Manuel ^g   Bucher, Heiner C ^a,g  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bayesian statistics; Epidemiologic methods; Hierarchical regression; Highly active antiretroviral therapy; HIV; Metabolic syndrome

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC SYNDROME X; MODELS, STATISTICAL; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; STAVUDINE; SWITZERLAND;

EID: 67349149411     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2008.07.015     Document Type: Article

References (55)

1. Peduzzi P., Concato J., Feinstein A.R., and Holford T.R. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48 (1995) 1503-1510
2. Peduzzi P., Concato J., Kemper E., Holford T.R., and Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49 (1996) 1373-1379
3. Greenland S. When should epidemiologic regressions use random coefficients?. Biometrics 56 (2000) 915-921
4. Witte J.S., Greenland S., Haile R.W., and Bird C.L. Hierarchical regression analysis applied to a study of multiple dietary exposures and breast cancer. Epidemiology 5 (1994) 612-621
5. Thomas D., Langholz B., Clayton D., Pitkaniemi J., Tuomilehto-Wolf E., and Tuomilehto J. Empirical Bayes methods for testing associations with large numbers of candidate genes in the presence of environmental risk factors, with applications to HLA associations in IDDM. Ann Med 24 (1992) 387-392
6. Friis-Moller N., Sabin C.A., Weber R., d'Arminio M.A., El Sadr W.M., Reiss P., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
7. Friis-Moller N., Reiss P., Sabin C.A., Weber R., Monforte A., El Sadr W., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
8. Moyle G.J. Lipid abnormalities during ART: it's the drug, not the class. AIDS Read 14 (2004) 15-16
9. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl 1 (2004) S5-S10
11. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
12. Glass T.R., Ungsedhapand C., Wolbers M., Weber R., Vernazza P.L., Rickenbach M., et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 7 (2006) 404-410
13. Alberti K.G.M.M., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
14. Carlin J.B., Wolfe R., Coffey C., and Patton G.C. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete-time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat Med 18 (1999) 2655-2679
15. Breslow N. Covariance adjustment of relative-risk estimates in matched studies. Biometrics 38 (1982) 661-672
16. Fahrmeir L., and Tutz G. Multivariate statistical modelling based on generalized linear models (1994), Springer-Verlag, New York 318-325
17. Steyerberg E.W., Eijkemans M.J., Harrell Jr. F.E., and Habbema J.D. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19 (2000) 1059-1079
18. Greenland S., Schwartzbaum J.A., and Finkle W.D. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 151 (2000) 531-539
19. Ioannidis J.P. Contradicted and initially stronger effects in highly cited clinical research. JAMA 294 (2005) 218-228
20. Greenland S. Methods for epidemiologic analyses of multiple exposures-a review and comparative-study of maximum-likelihood, preliminary-testing, and empirical-Bayes regression. Stat Med 12 (1993) 717-736
21. Witte J.S., and Greenland S. Simulation study of hierarchical regression. Stat Med 15 (1996) 1161-1170
22. Greenland S. Principles of multilevel modelling. Int J Epidemiol 29 (2000) 158-167
23. Breslow N.E., and Clayton D.G. Approximate inference in generalized linear mixed models. J Am Stat Assoc 88 (1993) 9-25
24. Greenland S. Dose-response and trend analysis in epidemiology-alternatives to categorical analysis. Epidemiology 6 (1995) 356-365
25. Jerico C., Knobel H., Montero M., Ordonez-Llanos J., Guelar A., Gimeno J.L., et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28 (2005) 132-137
26. Bonfanti P., Ricci E., De Socio G., Zeme D., Carradori S., Penco G., et al. Metabolic syndrome: a real threat for HIV-positive patients? Results from the SIMONE study. J Acquir Immune Defic Syndr 42 (2006) 128-131
27. Jones R., Sawleshwarkar S., Michailidis C., Jackson A., Mandalia S., Stebbing J., et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 6 (2005) 396-402
28. Anderson P.L., Kakuda T.N., and Lichtenstein K.A. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 38 (2004) 743-753
29. Walker U.A., Setzer B., and Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16 (2002) 2165-2173
30. Yan Q., and Hruz P.W. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 40 (2005) 398-403
31. Gustafson P., and Greenland S. The performance of random coefficient regression in accounting for residual confounding. Biometrics 62 (2006) 760-768
32. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 312 (1996) 1215-1218
33. Sabin C.A., and Phillips A.N. Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrob Chemother 47 (2001) 371-375
34. Mamdani M., Sykora K., Li P., Normand S.L., Streiner D.L., Austin P.C., et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330 (2005) 960-962
35. Phillips A.N., Grabar S., Tassie J.M., Costagliola D., Lundgren J.D., and Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 13 (1999) 2075-2082
36. Eg Hansen A-B, Gerstoft J, Kirk O, Mathiesen L, Pedersen C, Nielsen H, et al. Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J Clin Epidemiol 2008;61:87-94.
37. Nolan D. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?. Drug Saf 28 (2005) 1069-1074
38. Bergersen B.M. Cardiovascular risk in patients with HIV infection-impact of antiretroviral therapy. Drugs 66 (2006) 1971-1987
39. Hertel J., Struthers H., Horj C.B., and Hruz P.W. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem 279 (2004) 55147-55152
40. Miller K.D., Jones E., Yanovski J.A., Shankar R., Feuerstein I., and Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351 (1998) 871-875
41. Murata H., Hruz P.W., and Mueckler M. Indinavir inhibits the glucose transporter isoform GLUT4 at physiologic concentrations. AIDS 16 (2002) 859-863
42. Noor M.A., Seneviratne T., Aweeka F.T., Lo J.C., Schwarz J.M., Mulligan K., et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16 (2002) F1-F8
43. Schwarz J.M., Lee G.A., Park S., Noor M.A., Lee J., Wen M., et al. Indinavir increases glucose production in healthy HIV-negative men. AIDS 18 (2004) 1852-1854
44. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M.A.H., Miller M.D., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients-a 3-year randomized trial. JAMA 292 (2004) 191-201
45. Podzamczer D., Ferrer E., Sanchez P., Gatell D.M., Crespo M., Fisac C., et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine-96-week results of a randomized study. J Acquir Immune Defic Syndr 44 (2007) 139-147
46. Ruane P.J., and DeJesus E. New nucleoside/nucleotide backbone options: a review of recent studies. J Acquir Immune Defic Syndr 37 (2004) S21-S29
47. Young B. The role of nucleoside and nucleotide reverse transcriptase inhibitor backbones in antiretroviral therapy. J Acquir Immune Defic Syndr 37 (2004) S13-S20
48. White A.J. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 77 (2001) 158-173
49. Cherry C.L., Nolan D., James I.R., McKinnon E.J., Mallal S.A., Gahan M.E., et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 42 (2006) 435-440
50. Squillace N, Guaraldi G, Orlando G, Roverato A, Nardini G, Beghetto B, et al. The role of virological and immunological parameters on the diagnosis of metabolic syndrome in HIV-associated lipodystrophy. In: Ninth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney, Australia [Abstract P38].
51. Psaty B.M., Koepsell T.D., Lin D., Weiss N.S., Siscovick D.S., Rosendaal F.R., et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47 (1999) 749-754
52. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Thiebaut R, et al. Relationship between use of stavudine and diabetes mellitius. In: Eigth International Congress on Drug Therapy in HIV Infection, 12-16 November 2006, Glasgow, UK [Abstract PL9.5].
53. Worm SW, Sabin CA, El Sadr WM, Reiss P, D'Arminio Monforte A, Rickenbach M, et al. The metabolic syndrome at baseline in the D:A:D study. In: Eighth International Congress on Drug Therapy in HIV Infection, 12-16 November 2006, Glasgow, UK. [Abstract P124].
54. Worm SW, Sabin CA, Reiss P, El-Sadr W, D'Arminio Monforte A, Law M, et al. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components: data from the D:A:D Study. In: Fourteenth Conference on Retrovirus and Opportunistic Infections, 25-28 February 2007, Los Angeles, USA. A815.
55. Witte J.S., Greenland S., Kim L.L., and Arab L. Multilevel modeling in epidemiology with GLIMMIX. Epidemiology 11 (2000) 684-688